Cargando…
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and survival of patients with IPF observed in the multi-nationa...
Autores principales: | Jovanovic, Dragana M., Šterclová, Martina, Mogulkoc, Nesrin, Lewandowska, Katarzyna, Müller, Veronika, Hájková, Marta, Studnicka, Michael, Tekavec-Trkanjec, Jasna, Littnerová, Simona, Vašáková, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145164/ https://www.ncbi.nlm.nih.gov/pubmed/35624513 http://dx.doi.org/10.1186/s12931-022-02033-6 |
Ejemplares similares
-
Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries
por: Kolonics-Farkas, Abigél Margit, et al.
Publicado: (2021) -
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
por: Kolonics-Farkas, Abigél M., et al.
Publicado: (2020) -
The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis
por: Tran, Tanja, et al.
Publicado: (2020) -
Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone
por: Májek, Ondřej, et al.
Publicado: (2022) -
Biomarkers of Fibroproliferative Healing in Fibrosing Idiopathic Interstitial Pneumonias
por: Vasakova, Martina, et al.
Publicado: (2012)